Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Japan’s health ministry approved a throng of new medicines on January 18 including Pfizer’s respiratory syncytial virus (RSV) vaccine, the second of its kind in the country, and Ultragenyx’s cholesterol therapy Evkeeza (evinacumab). Pfizer’s RSV jab Abrysvo gained the nod…
To read the full story
Related Article
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
- Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
- Pfizer’s RSV Vaccine Abrysvo Now Available in Japan
June 3, 2024
- Alexion’s Voydeya Marks 1st Application of “Early Launch Premium,” but Rate Fully Axed
April 11, 2024
REGULATORY
- MOF Panel Pushes for Full Drug Price Revision in FY2027: Budget Proposal
November 20, 2026
- Mumps Shots Gain Strong Backing as Japan Weighs FY2027 NIP Priorities
November 20, 2026
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- Pharma Prods LDP to Rethink CEA Expansion, Project Team to Compile Proposal
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026





